Hong Kong-based Insilico Medicine partnered with a US firm to build an AI model focused on extending human life. The collaboration leverages drug discovery algorithms to identify longevity markers. This move shifts the company's focus toward aging as a treatable condition. Practitioners should monitor whether these models translate into viable clinical trials.